{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:10:05Z","timestamp":1756278605123,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,3,24]]},"abstract":"<jats:p>A 37-year-old man with hepatitis C virus (HCV) genotype 3A developed renal failure. In 2007, the patient received a renal transplant and started receiving tacrolimus (Tac); the transplant subsequently failed. In April 2015, the patient restarted haemodialysis and in May initiated sofosbuvir 400\u2009mg and ribavirin 400\u2009mg daily. Baseline Tac level was 6.6\u2009ng\/mL and haemoglobin (Hb) was 10.3\u2009g\/dL. The patient then left the country for vacation and Hb was found to be dramatically low at 3.7\u2009g\/dL on return on 5 August. Ribavirin was put on hold, while darbepoetin dose was increased. On 23 August, Tac level was found undetectable; hence, dosage was increased. Hb eventually bounced back to &gt;10\u2009g\/dL in October and Tac to 7.2\u2009ng\/mL; ribavirin was restarted at 200\u2009mg three times weekly. HCV RNA level was undetectable at 3 months and remained undetectable 12 weeks after therapy finished.<\/jats:p>","DOI":"10.1136\/bcr-2017-222477","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T05:15:18Z","timestamp":1524028518000},"page":"bcr-2017-222477","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis"],"prefix":"10.1136","volume":"2018","author":[{"given":"Hin-Yee","family":"Liu","sequence":"first","affiliation":[{"name":"Dialysis Unit, Fraser Health, Abbotsford, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Yuen Shan","family":"Cheung","sequence":"additional","affiliation":[{"name":"Dialysis Unit, Fraser Health, Abbotsford, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Elizabeth","family":"Cooper","sequence":"additional","affiliation":[{"name":"Dialysis Unit, Fraser Health, Abbotsford, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/692408"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1137-x"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.165076"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307080"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000161","article-title":"Does therapeutic drug monitoring of ribavirin in HCV genotype 3 treatment with sofosbuvir and ribavirin still have a role?","volume":"37","author":"Brochot","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.9","unstructured":"Maviret. Product monograph including patient medication information. St-Laurent (QC: Abbvie Corporation, 2017."},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.10","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13102"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.11","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90153-1"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-9556(25)07474-4","article-title":"FK 506) in rabbits. Role of red blood cell binding in hepatic clearance","volume":"21","author":"Piekoszewski","year":"1993","journal-title":"Drug Metabolism & Disposition"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.13","first-page":"610","article-title":"Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion","volume":"25","author":"Chow","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"2025082623385572000_2018.apr17_2.bcr-2017-222477.14","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182708edf"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-222477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:39:04Z","timestamp":1756276744000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-222477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":14,"alternative-id":["10.1136\/bcr-2017-222477"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-222477","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,4,18]]}}}